Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis

Son of Sevenless 1 (SOS1) is a dual guanine nucleotide exchange factor (GEF) that activates the small GTPases RAC and RAS. Although the molecular mechanisms of RAS GEF catalysis have been unveiled, how SOS1 acquires RAC GEF activity and what is the physio-pathological relevance of this activity is much less understood. Here we show that SOS1 is tyrosine phosphorylated on Y1196 by ABL. Phosphorylation of Y1196 controls SOS1 inter-molecular interaction, is required to promote the exchange of nucleotides on RAC in vitro and for platelet-derived growth factor (PDGF) activation of RAC- and RAC-dependent actin remodeling and cell migration. SOS1 is also phosphorylated on Y1196 by BCR-ABL in chronic myelogenous leukemic cells. Importantly, in these cells, SOS1 is required for BCR-ABL-mediated activation of RAC, cell proliferation and transformation in vitro and in a xenograft mouse model. Finally, genetic removal of Sos1 in the bone marrow-derived cells (BMDCs) from Sos1fl/flmice and infected with BCR-ABL causes a significant delay in the onset of leukemogenesis once BMDCs are injected into recipient, lethally irradiated mice. Thus, SOS1 is required for full transformation and critically contribute to the leukemogenic potential of BCR-ABL

Extensive Gene-Specific Translational Reprogramming in a Model of B Cell Differentiation and Abl-Dependent Transformation

To what extent might the regulation of translation contribute to differentiation programs, or to the molecular pathogenesis of cancer? Pre-B cells transformed with the viral oncogene v-Abl are suspended in an immortalized, cycling state that mimics leukemias with a BCR-ABL1 translocation, such as Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Inhibition of the oncogenic Abl kinase with imatinib reverses transformation, allowing progression to the next stage of B cell development. We employed a genome-wide polysome profiling assay called Gradient Encoding to investigate the extent and potential contribution of translational regulation to transformation and differentiation in v-Abl-transformed pre-B cells. Over half of the significantly translationally regulated genes did not change significantly at the level of mRNA abundance, revealing biology that might have been missed by measuring changes in transcript abundance alone. We found extensive, gene-specific changes in translation affecting genes with known roles in B cell signaling and differentiation, cancerous transformation, and cytoskeletal reorganization potentially affecting adhesion. These results highlight a major role for gene-specific translational regulation in remodeling the gene expression program in differentiation and malignant transformation

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Mental Fatigue and Soccer: Current Knowledge and Future Directions

© 2018, Springer International Publishing AG, part of Springer Nature. Fatigue is a complex state with multiple physiological and psychological origins. However, fatigue in soccer has traditionally been investigated from a physiological perspective, with little emphasis on the cognitive demands of competition. These cognitive demands may induce mental fatigue, which could contribute to the fatigue-related performance decrements observed during and after soccer matches. Recent research investigating the relationship between mental fatigue and soccer-specific performance supports this suggestion. This leading article provides an overview of the research in this emerging field, outlining the impact of mental fatigue on soccer-specific physical, technical, decision-making, and tactical performances. The second half of this review provides directions for future research in response to the limitations of the existing research. Emphasis is placed on translating the current body of knowledge into practical applications and developing a greater understanding of the mechanisms underpinning the negative impact of mental fatigue on soccer performance. A conceptual model is presented to help direct this future research

Mental Fatigue in Football: Is it Time to Shift the Goalposts? An Evaluation of the Current Methodology

© 2018, Springer Nature Switzerland AG. Research in football for a long time has focused on the physical nature of fatigue as opposed to its mental aspects. However, since 2016, six original articles have investigated the effects of induced mental fatigue in football on isolated physical, skill and decision-making performance tests, along with physical, technical and tactical performance outcomes in small-sided games. Whilst these studies have overall shown a negative impact of mental fatigue on task performance, this current opinion aims to critically examine the methodological approach to this problem, most notably the lack of ecological validity when inducing mental fatigue and the present approach to measuring mental fatigue using visual analogue scales (VAS). It is suggested that future research on mental fatigue in football may benefit from the use of surveys/interviews to understand the true cognitive demands of elite football players. Additionally, future research should aim to reduce the reliance on using VAS to measure mental fatigue as results from this tool may be confounded by several response biases. In conclusion, this article highlights the need for mentally fatiguing tasks that adequately represent football-associated mental fatigue and assessments of mental fatigue that minimise the confounding effect of response bias

Reliability and stability of performances in 400-m swimming and 1500-m running

PURPOSE: To assess the reliability and stability of 400-m swimming and 1500-m running competitions to establish the number of samples needed to obtain a stable pacing profile. Coaches, athletes, and researchers can use these methods to ensure that sufficient data are collected before training and race strategies are constructed or research conclusions are drawn. METHOD: Lap times were collected from 5 world and European championship finals between 2005 and 2011, resulting in the capture of data from 40 swimmers and 55 runners. A cumulative mean for each lap was calculated, starting with the most recent data, and the number of races needed for this to stabilize to within 1% was reported. Typical error for each lap was calculated for athletes who had competed in more than 1 final. RESULTS: International swimmers demonstrated more reproducible performances than runners in 3 of the 4 laps of the race (P < .01). Variance in runners' lap times significantly decreased by 1.7-2.7% after lap 1, whereas variance in swimmers' lap times tended to increase by 0.1-0.5% after lap 1. To establish a stable profile, at least ten 400-m swimmers and forty-four 1500-m runners must be included. CONCLUSIONS: A stable race profile was observed from the analysis of 5 events for 1500-m running and 3 events for 400-m swimming. Researchers and athletes can be more certain about the pacing information collected from 400-m swimming than 1500-m running races, as the swimming data are less variable, despite both events being of similar duration